If this is the case, the NR2A and NR2B antagonists (such as Con-T and Con-G) tested in the present study could be potentially used to control or prevent DAC excitotoxicity in neurodegenerative diseases of the retina. This evidence concerns the gene GRIN2B and neurodegenerative disease.